These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37072866)

  • 1. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
    Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
    Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
    Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
    J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
    Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
    Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
    Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
    Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes.
    Ling Y; Li N; Li L; Guo C; Wei J; Yuan P; Tan F; Tao X; Wang S; Wang Z; Wu N; Wang J; Ying J; Gao S; He J
    NPJ Precis Oncol; 2020 Dec; 4(1):32. PubMed ID: 33299121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.
    Deng H; Liang H; Chen J; Wang W; Li J; Xiong S; Cheng B; Li C; Chen Z; Wang H; Zheng J; Guo Z; He J; Liang W
    Transl Lung Cancer Res; 2022 Dec; 11(12):2364-2381. PubMed ID: 36636407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
    Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
    BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
    Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1005-1024. PubMed ID: 38319500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
    Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
    Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Percentage" and "size" of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Sun W; Qu L; Wu J; Liu X; Wang C; Jiang Y; Liu Y; Chen M; Wang X; Lin D
    Hum Pathol; 2024 Jul; 149():1-9. PubMed ID: 38782102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
    Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis.
    Zhai WY; Zhao ZR; Chen S; Yu H; Lin YB; Wang YZ; Long H
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
    Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
    Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
    Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
    Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma.
    Gu C; Teng X; Sun X; Liu J; Zhu Z; Zhang L; Wu Z; Zou R; Pang J; Lyu X
    BMC Cancer; 2024 May; 24(1):585. PubMed ID: 38741038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Deutsch JS; Cimino-Mathews A; Thompson E; Provencio M; Forde PM; Spicer J; Girard N; Wang D; Anders RA; Gabrielson E; Illei P; Jedrych J; Danilova L; Sunshine J; Kerr KM; Tran M; Bushong J; Cai J; Devas V; Neely J; Balli D; Cottrell TR; Baras AS; Taube JM
    Nat Med; 2024 Jan; 30(1):218-228. PubMed ID: 37903504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
    Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
    Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appraisal of a revised lymph node classification system for esophageal squamous cell cancer.
    Dhar DK; Hattori S; Tonomoto Y; Shimoda T; Kato H; Tachibana M; Matsuura K; Mitsumoto Y; Little AG; Nagasue N
    Ann Thorac Surg; 2007 Apr; 83(4):1265-72. PubMed ID: 17383324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.